top of page

June 2020 // Communication

  • andreachicca797
  • Jun 24, 2020
  • 1 min read

Updated: Mar 19, 2021

Synendos Therapeutics received a prestigious European grant (SME Instrument Phase I, TWO-BIRDS project ) that helped the company to head towards clinical trials. The European commission is now reporting about the results and the perspectives to treat post-traumatic stress disorder (PTSD) and other neuropsychiatric diseases. Read the full article here.



Recent Posts

See All
March 2025 // Communication

Synendos has been selected as a finalist of the Swiss Economic Award 2025 in the category Deeptech / Life Sciences. LinkedIn post

 
 
March 2025 // Events & Communication

Synendos has been selected for the Bio-Neuroscience Award for the "Best Pitch" after our CEO Andrea Chicca's presentation on our clinical...

 
 
July 2024 // Communication

Synendos is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in...

 
 
bottom of page